Participated · Equity · Mar 2021

Adapttech is a biomedical company that developed the INSIGHT system to simplify fitting lower limb prosthetics and to monitor patient rehabilitation. The INSIGHT system aims to deliver cost savings and enhanced comfort for patients while making it easier for clinicians to fit prosthetics. The company has gained FDA proof of concept approval for its system in the U.S. and has made initial sales to clinicians in America and Europe. Adapttech intends to use new funding to bolster its team with five new jobs, including hiring a CTO, and to further develop its product pipeline. The company has raised £7.3m in total funding to date. Adapttech is based in Birmingham, UK, and also has presences in Porto, Portugal and Greenville, NC. Adapttech provides INSIGHT, an integrated system that combines a 3D scanner, sensors, wearable technology and a mobile app to simplify reaching a comfortable prosthetic socket and to monitor patients' rehabilitation. INSIGHT is now generally available after successful outcome studies at two prosthetics clinics in the United States, where validated tests for health, function, satisfaction and pain level verified the system's effectiveness. The company is led by founder Frederico Carpinteiro and chairman Stuart Mead. Adapttech intends to use newly raised funds to develop new technologies and grow sales of its INSIGHT system. The company raised capital to support product development and commercial expansion in its target markets. Adapttech is based in Birmingham, UK. Adapttech develops the INSIGHT™ system to improve fitting of lower-limb prostheses and monitor rehabilitation. INSIGHT™ comprises a scanner that creates a 3D model of the prosthetic socket, a wearable device that fits between the residual limb and prosthesis to gather data and pinpoint problem areas, and an app through which healthcare professionals can access results. The company was founded in 2015 by biomedical engineers Frederico Carpinteiro and Mario Espinoza and recently moved its headquarters from Portugal to the Institute of Translational Medicine in Birmingham. Adapttech raised £1.3m to finalize clinical trials and commercialize the product. Backers named in the raise include the MEIF Proof of Concept & Early Stage Fund (managed by Mercia), Mercia’s EIS funds, Hovione Capital and private investors. The proceeds will be used to complete clinical validation and support commercialization efforts.

Participated · Equity · Mar 2021

Vaxdyn develops multi‑pathogen vaccine candidates aimed at preventing infections caused by antibiotic‑resistant bacteria. Headquartered in Seville, Spain, the company works with an international network of collaborators to target high‑risk populations (chronic lung, liver, kidney disease, immunocompromised patients, nursing‑home and hospital settings). Its vision is to create specific immunity in these groups and to reduce antibiotic use worldwide following a One‑Health approach. Recent financing activity includes share acquisitions by Bionova Capital and Arquimea Group (each valued at €300,000 in two tranches) and a €100,000 capital increase from the Mind the Gap Program. Vaxdyn also benefits from CARB‑X support: up to $7.3 million in non‑dilutive, milestone‑based funding to advance its lead vaccine candidate through a first‑in‑human study. Strategic investors are positioned to contribute sector expertise and cross‑sector technological support to the company’s vaccine development efforts.